EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Natera's enterprise value is $11,447 Mil.
Natera's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $1,083 Mil. Therefore, Natera's EV-to-Revenue for today is 10.57.
The historical rank and industry rank for Natera's EV-to-Revenue or its related term are showing as below:
NTRA'
s EV-to-Revenue Range Over the Past 10 Years
Min: 0.86 Med: 5.38 Max: 26.11
Current: 10.57
During the past 11 years, the highest EV-to-Revenue of Natera was 26.11. The lowest was 0.86. And the median was 5.38.
NTRA's EV-to-Revenue is ranked worse than 83.19% of 226
companies
in the Medical Diagnostics & Research industry
Industry Median: 3.155
vs NTRA: 10.57
As of today (2024-05-09), Natera's stock price is $95.66.
Natera's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $9.40. Therefore, Natera's PS Ratio for today is 10.18.
Natera EV-to-Revenue Historical Data
The historical data trend for Natera's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Natera's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Natera's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Natera's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Natera's EV-to-Revenue falls into.
Natera's current Enterprise Value is $11,447 Mil.
Natera's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,083 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Natera's share price for today is $95.66.
Natera's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.40.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Natera EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Natera's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NTRA has been successfully added to your 